Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

doi:10.3748/wjg.v20.i3.786

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 3

This Article

(334)

(331)

(0)

(7496)

(20)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Brief Article

World J Gastroenterol. Jan 21, 2014; 20(3): 786-794
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786

Table 2 Incidence of adverse events in 44 patients with cirrhosis and hepatocellular carcinoma undergoing treatment with sorafenib n (%)

Adverse events	Statistics
Fatigue	29 (65.9)
Grade 1	11 (25.0)
Grade 2	11 (25.0)
Grade 3	7 (15.9)
Bleeding	7 (15.9)
Grade 1	3 (6.8)
Grade 2	1 (2.3)
Grade 3	3 (6.8)
Hand-foot syndrome	14 (31.8)
Grade 1	7 (15.9)
Grade 2	7 (15.9)
Grade 3	0 (0.0)
Diarrhea	15 (34.1)
Grade 1	6 (13.6)
Grade 2	8 (18.2)
Grade 3	1 (2.3)
Hepatic grade 3¹AEs	8 (18.2)
Other AEs²	20 (45.5)

¹An increase in aminotranspherase and bilirubin after starting sorafenib was observed in all patients;

²Including rash, hypertension, alopecia, diabetes, mucositis, abdominal pain, voice changes. All grades were evaluated according to Common Terminology Criteria for Adverse Event version 3.0. AEs: Adverse events.

Full Size Table

Citation: Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794
URL: https://www.wjgnet.com/1007-9327/full/v20/i3/786.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i3.786

Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794 [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.